Theorem Clinical Research has announced the formation of a strategic alliance with Decision Driver Analytics
Theorem Clinical Research
has announced the formation of a strategic alliance with
Decision Driver Analytics
(DDA) that will integrate health economics and outcomes research (HEOR), predictive modeling and definitive analysis to maximize return on investment for pharmaceutical and medical device research programs.
“The clinical studies that may prove a scientific point are really only one aspect of a successful drug or medical device development program,” said
John Potthoff, president and CEO of Theorem Clinical Research
. “Decision Driver Analytics’ product life cycle value analysis and exceptional economic insight help clients make high-value decisions with confidence throughout the entire development process.”
Decision Driver Analytics was founded in 2006 by Elizabeth Brooks, Ph.D., to provide accessible health economics analysis and strategies that can be used to drive key product decisions for manufacturers and developers. A recognized expert in her field, Brooks has designed numerous health economics models and market development programs. Backed by a team of specialists including health economists, epidemiologists, biostatisticians, medical writers and reimbursement experts, Brooks is known for an ability to make statistical results understandable and actionable.
“Knowing the right answers to key questions at critical decision points in the development process can make the difference between having the latest blockbuster or an expensive failure,” Potthoff said. “We believe this alliance helps drive projects for clients in ways that will achieve both regulatory and marketing success.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.